Chifeng Rongjitang Pharmaceutical Co. Ltd.

Pramipexole hydrochloride tablets provided by Chifeng Sailintai Pharmaceutical Co., Ltd. were used as the test preparation. According to the relevant provisions of the bioequivalence study, the absorption rate and extent of pramipexole hydrochloride tablets (trade name: Senforo®, reference preparation) produced by Boehringer Ingelheim Pharma GmbH were compared in healthy Chinese adults to investigate the bioequivalence of the two preparations.

Main study purpose The purpose of this study is to use Rosuvastatin Calcium Tablets provided by Chifeng Sailintai Pharmaceutical Co., Ltd. as the test preparation, and conduct human bioavailability and bioequivalence tests with Rosuvastatin Calcium Tablets (trade name: Crestor®, reference preparation) produced by IPR Pharmaceuticals, INCORPORATED (licensee: Astrazeneca UK Limited) according to the relevant provisions of bioequivalence tests. Secondary study purpose Observe the safety of the test preparation Rosuvastatin Calcium Tablets and the reference preparation Crestor® in healthy subjects.

The purpose of this study was to study the pharmacokinetic characteristics of a single fasting oral dose of bismuth potassium citrate tablets [120 mg (calculated as Bi2O3)] developed by Chifeng Sailintai Pharmaceutical Co., Ltd.; using bismuth potassium citrate tablets [Gastrodenol®, 120 mg (calculated as Bi2O3)] produced by TORA LABORATORIES, S.L. as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.